ReviewBMJ global health2023
Negotiating public-health intellectual property licensing agreements to increase access to health technologies: an insider's story.
Review in BMJ global health, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- The public health impact of the Medicines Patent Pool increases with the fragmentation of intellectual property rights.Nature biotechnology · 2026Article
- Making Advanced Therapies Affordable and Accessible: Two Strategic Approaches.Developing world bioethics · 2026Article
- TRIPS flexibilities help change policy and practice to increase access to medicines: evidence from 2001 to 2024.BMJ global health · 2026Article
- The Regulatory Landscape of Biobanks In Europe: From Accreditation to Intellectual Property.Current genomics · 2025Review
- Why is roll-out of long-acting PrEP agents so slow?Current opinion in HIV and AIDS · 2025Review
- Advancing global antibiotic research, development and access.Nature medicine · 2024Review
- Intellectual property licensing of therapeutics during the COVID-19 crisis: lessons learnt for pandemic preparedness and response.Globalization and health · 2024Article
- Ethical and Practical Considerations for an Agreement to Ensure Equitable Vaccine Access Comment on "More Pain, More Gain! The Delivery of COVID-19 Vaccines and the Pharmaceutical Industry's Role in Widening the Access Gap".International journal of health policy and management · 2024Article
- 'Our project, your problem?' A case study of the WHO's mRNA technology transfer programme in South Africa.PLOS global public health · 2024Article
- Evolutionary trend analysis of the pharmaceutical management research field from the perspective of mapping the knowledge domain.Frontiers in health services · 2024Review
- Novel approaches to enable equitable access to monoclonal antibodies in low- and middle-income countries.PLOS global public health · 2024Review
- Lessons learnt from COVID-19 to reduce mortality and morbidity in the Global South: addressing global vaccine equity for future pandemics.BMJ global health · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Public health voluntary licensing of intellectual property has successfully been applied to increase access to medicines in certain disease areas, producing health benefits and economic savings, particularly in low-income and middle-income countries. There is however limited understanding of the intricacies of the approach, the modalities by which it works in practice, its levers and the trade-offs made. Such knowledge may be critical in deciding what role licensing should have in pandemic preparedness and equitable access to health technologies more broadly. This paper examines the case for licensing, the considerations for balancing public health needs, the challenges of negotiations, and the processes for validating proposed agreements. No access mechanism is perfect, but evidence suggests that public-health licensing has an important role to play, although it remains underused. Understanding some of the realities, strengths, limitations and complexities of applying the model may help calibrate expectations and develop incentives to expand its applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.